The Orally Bioavailable GSPT1/2 Degrader SJ6986 Exhibits In Vivo Efficacy in Acute Lymphoblastic Leukemia

Investigators reported in vitro and in vivo testing of the activity of a novel Cereblon modulator, SJ6986, in a panel of acute lymphoblastic leukemia cell lines and xenografts.